Saturday, September 15, 2012

IRX4204 as a Potential Disease-Modifying Treatment for Alzheimer's Disease




Caregivers, and healthcare professionals, here is some great information


Here is a great dementia resource for caregivers and healthcare professinals,

Your residents will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two

Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition

Posted in life sciences

Associated Press


Io Therapeutics, Inc. announced today the presentation of data from preclinical studies of its Retinoid X Receptor (RXR) agonist compound IRX4204 in animal models of Alzheimer's disease, at the 6th Neurodegenerative Conditions Research and Development conference, currently being held in San Francisco, CA. The presentation titled "Investigation of the RXR-specific agonist IRX4204 as a Disease-Modifying Agent of Alzheimer's Disease Neuropathology and Cognitive Impairment" was presented by Dr. Giulio Maria Pasinetti.
The studies were directed by Dr. Pasinetti, M.D., Ph.D., The Saunders Family Chair and Professor in Neurology, and Director, Center of Excellence for Novel Approaches to Neurotherapeutics, in the Department of Neurology of Mount Sinai School of Medicine in New York City. Dr. Pasinetti said, "The data presented today include studies demonstrating attenuation of cognitive deterioration in IRX4204-treated mouse model of Alzheimer's disease through promotion of electophysiological features in the brain associated with retention of memory function."
Io Therapeutics, Inc. also announced the establishment of a sponsored research agreement with Mount Sinai School of Medicine to conduct additional studies of this compound in Alzheimer's disease.
Rosh Chandraratna, Ph.D., Chief Scientific Officer of Io Therapeutics, said "IRX4204 is a highly specific and very potent agonist of the RXR nuclear receptor pathways, which has at least a 1000-fold difference in the concentrations that activate RXR versus concentrations that activate RAR nuclear receptors. This specificity and potency distinguishes IRX4204 from bexarotene, an RXR agonist compound which also has been reported to be active in animal models of Alzheimer's disease." Dr. Chandraratna added, "IRX4204 has previously completed a phase I/II clinical trial in patients with a variety of solid tumors, in which it was well tolerated for up to 20 months without observation of typical RAR-related toxicities, and in which findings supporting potential clinical activity in a variety of types of cancer were observed."
Martin Sanders, M.D., Chairman and Chief Executive Officer of Io Therapeutics, said, "IRX4204 is currently being evaluated in a phase II clinical trial in men with advanced prostate cancer. The company plans to file an additional IND for evaluation of IRX4204 in patients with Alzheimer's disease, with clinical studies in Alzheimer's patients anticipated to start in 2013." Dr. Sanders continued, "The treatment of Alzheimer's disease remains a serious unmet medical need which IRX4204 may be able to address. Recent failures of phase III clinical trials of two different monoclonal antibodies specific for beta amyloid have reinforced the need for development of additional types of interventions for this devastating disease, which currently afflicts more than 5 million Americans and may afflict 16 million Americans by 2050 according data from the Alzheimer's Association. Dr. Pasinetti's studies, combined with data from other laboratories investigating the less specific RXR agonist bexarotene, support that RXR agonists have potential for slowing, and possibly reversing pathology and cognitive deficits in Alzheimer's disease patients."
About Io Therapeutics: Io Therapeutics, Inc. is a privately held company headquartered in Santa Ana, California, focused on the development of treatments for Alzheimer's disease, cancer and autoimmune diseases. For more information on Io-Therapeutics and its product pipeline see: www.io-therapeutics.com

Friday, September 14, 2012

Investigators identify gene linking cataracts and Alzheimer's disease



Caregivers, and healthcare professionals, here is some great information


Here is a great dementia resource for caregivers and healthcare professinals,

Your residents will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two

Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition

Medical Xpress

In a recent study, investigators at Boston University Schools of Medicine (BUSM) and Public Health (BUSPH) identified a gene linking age-related cataracts and Alzheimer's disease. The findings, published online in PLoS ONE, contribute to the growing body of evidence showing that these two diseases, both associated with increasing age, may share common etiologic factors.
Gyungah Jun, PhD, from the departments of medicine, ophthalmology and biostatistics at BUSM and BUSPH, served as the study's lead author. Lindsay A. Farrer, PhD, professor of medicine, neurology, ophthalmology, genetics & genomics, epidemiology and biostatistics and chief of the Biomedical Genetics Section at BUSM, was the study's senior author. Using the Framingham Offspring Eye Study cohort, investigators looked at brain MRI findings on or after 10 years from the original eye exam and concluded that there was a significant correlation between a quantitative measure of cortical cataract and several Alzheimer's disease-related measures of brain degeneration, in particular volume of the temporal horn which is a brain structure that is progressively enlarged in patients with Alzheimer's disease. Another strong correlation in these same individuals, between cortical cataract formation and poorer performance on several cognitive tests administered at the time of the MRI scan, further supports this link. With such a link not confounded by age or sex, the investigators then performed a genome-wide association study looking at nearly 190,000 single-nucleotide polymorphisms (SNPs), or DNA sequence variations. Three intronic (non-coding) SNPs in the gene encoding δ-catenin came to the fore. This protein is a key component in cell adherence and formation of cell junctional structures. Previously, δ-catenin was also implicated in brain and eye development, but not directly in either cataracts or Alzheimer's disease. To establish a more direct link of δ-catenin to Alzheimer's disease, the researchers transfected into neuronal cells δ-catenin bearing a mutation near the location of the top-associated SNPs and observed a significant and specific increase in the toxic form of amyloid β, the protein that aggregates in Alzheimer brains and thought to be central to development of the disorder. In addition, the researchers found increased deposits of δ-catenin in lens tissue obtained from autopsy-confirmed Alzheimer's cases but not from subjects lacking Alzheimer's-associated neuropathology. "Though much work remains to be done, a link between cataracts and Alzheimer's disease supports the idea of a systemic rather than brain-limited focus for processes leading to Alzheimer's disease," said Farrer. "This study gives hope that we are moving toward earlier diagnosis and new treatment targets for this debilitating disease." Journal reference: PLoS ONE Provided by Boston University Medical Center 

Tuesday, September 11, 2012

New Alzheimer’s Drug Researched at Cleveland Clinic


Caregivers, and healthcare professionals, here is some great information

Here is a great dementia resource for caregivers and healthcare professinals,


Your residents will love the Amazon Kindle Fire


Here is information on being the best caregiver you can be


Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two


Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition

CLEVELAND — Research being done in Cleveland may lead to a drug to treat people with Alzheimer’s Disease. While it is not being looked at as a cure, it is hoped the potential drug will help slow down the progression of the fatal, brain disease.
About five million Americans now suffer with Alzheimer’s. The predominantly age-related disease slowly robs one’s memory and thinking skills.
Dr. David Brown with Cleveland Clinic Anesthesiology Institute said the effects of Alzheimer’s are irreversible.
“That results from some inflammation in the brain that leads to plaqueing with specific proteins that end up in a sense short circuiting part of the brain,” said Brown.
Brown is among Cleveland Clinic researchers looking at how inflammation in the brain and nerve pain affects the progression of Alzheimer’s. The research involves a compound known as MDA-7.
“It was originally designed for breast cancer patients — to minimize women’s discomfort with the neural injury that they sometimes get from the chemo from breast cancer,” added Brown.
Researcher Dr. Mohamed Naguib thought if MDA-7 could help breast cancer patients, perhaps its anti-inflammatory properties could have a similar effect on the brain of an Alzheimer’s patient.
Naguib said it is hoped that MDA-7 could slow down the devastating effects of the disease.
“Hopefully, our hypothesis is that if administered well in advance before the development of the disease, we can retard the development of the disease itself. Or, hopefully, we can minimize it.”
The research is now being done on animals, but with increased funding and FDA approval, the Cleveland Clinic researcher hope the MDA-7 compound could be tested on Alzheimer’s patients.
Brown said the research has been called promising and that the MDA-7 compound actually does seem to minimize the problems associated with Alzheimer’s disease.
“If you could give back those years for our seasoned folks or family members,” said Brown. “What a blessing that would be.”

Sunday, September 9, 2012

Alzheimer's experts provide strategic roadmap to tackle the disease


Caregivers, and healthcare professionals, here is some great information

Here is a great dementia resource for caregivers and healthcare professinals,


Your residents will love the Amazon Kindle Fire


Here is information on being the best caregiver you can be


Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two


Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition

Medical Xpress

This week, a strategic roadmap to help to the nation's health care system cope with the impending public health crisis caused Alzheimer's disease and related dementia will be published in Alzheimer's & Dementia: The Journal of the Alzheimer's Association. The plan aims to link the latest scientific findings with clinical care and bring together patients, families, scientists, pharmaceutical companies, regulatory agencies, and advocacy organizations behind a common set of prioritized goals. The consensus document is the outcome of a June meeting of leading Alzheimer's researchers, advocates and clinicians, who gathered as part of the Marian S. Ware Alzheimer Program at the University of Pennsylvania.
Today, 5.4 million people are living with the disease, and more than 15 million Americans are caring for persons with Alzheimer's and other dementias, according to the Alzheimer's Association. Alzheimer's disease is the sixth-leading cause of death in the United States and the only cause of death among the top 10 in the United States that cannot be prevented, cured, or even slowed. "Our plan aims to provide good quality care for affected patients and families, advance our understanding of the pathophysiology and natural history of AD and other dementias, develop effective treatments to slow or prevent these diseases, and translate scientific advances successfully into policy and practice," the authors wrote. The experts developed a prioritized and integrated set of recommendations after meeting in June at Penn. Four workgroups, focusing on Biomarkers, Clinical Care and Health Services Research, Drug Development and Health Economics, Policy and Ethics, had met separately leading up to the June conference. The document details recommendations from each group, and prioritizes the key recommendations from the paper, including: Speed the translation of research discoveries into clinical practice by revising the regulatory process and incentivize the pharmaceutical industry to develop AD drugs. Establish a diverse registry of older adults with and without dementia. Develop a risk stratification model that incorporates demographic, genetic, biologic, cognitive and environmental markers. Increase support to advance valuable care for patients affected with AD and their caregivers. Consider legislation requiring that, until the clinical value of biomarkers is fully understood, information gained through biomarker studies cannot be considered in insurance or employment decisions. "This plan addresses the needs of a truly responsive health-care system: to integrate healthcare and social services as well as research and educational programs that support people with Alzheimer's, family members, and other caregivers along an individualized and changing illness trajectory ," said lead author Mary Naylor, PhD, RN. Dr. Naylor is the Marian S. Ware Professor in Gerontology; Director of NewCourtland Center for Transitions and Health at the University of Pennsylvania School of Nursing.
An accompanying editorial in the journal notes that the Ware Invitational Summit document may serve as an important tool for the upcoming U.S. National Plan to Address Alzheimer's Disease, as it provides concrete, achievable policy ideas, being mindful of budget constraints and cost-effectiveness. "Alzheimer's is an enormous and complex disease, and we believe that creative thinking, repurposing of existing funds, vigilance in reducing waste, and a constant focus on cost effectiveness will help make these recommendations a much-needed reality," said John Trojanowski, MD, PhD, senior author, director of the National Institute of Aging-funded Penn Alzheimer's Disease Core Center and is professor of Pathology and Laboratory Medicine in the Perelman School of Medicine at the University of Pennsylvania. "The diverse perspectives collected in this report provide constructive, ethical, cost-effective guidance for policymakers," said second author Jason Karlawish, MD, associate director of the Penn Memory Center and professor of Medicine and Medical Ethics and Health Policy in the Perelman School of Medicine. "The recommendations serve as a clear roadmap to bring caregivers, researchers, clinicians, and advocacy groups together and provide them much-needed support now and in the future." The Ware Invitational Summit brought together experts from academia; industry; government agencies and advocacy and nonprofit groups – including the meeting's co-convener, The Campaign to Prevent Alzheimer's Disease by 2020. The conference and editorial assistance were supported by the Marian S. Ware 2006 CWG Charitable Lead Annuity Trust and held at the University of Pennsylvania on June 20-21, 2012. If pieces of the plan are implemented globally - by government, private organizations and medical institutions alike - the authors' aspirations are that treatments can be developed within the next decade to improve or prevent AD; earlier diagnosis will give better options to patients ; and high-quality, effective care will be available to people with dementia throughout the course of their disease. Provided by University of Pennsylvania School of Medicine 

Wednesday, September 5, 2012

New PET tracer for Alzheimer's holds promise


Caregivers, and healthcare professionals, here is some great information

Here is a great dementia resource for caregivers and healthcare professinals,


Your residents will love the Amazon Kindle Fire


Here is information on being the best caregiver you can be


Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two


Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition

DOTmed.com

by Loren Bonner , staff writer
A Siemens Healthcare research team has moved forward in testing a new PET imaging agent that may be used to detect Alzheimer's disease in patients.

Study results published in the August issue of the Journal of Alzheimer's Disease show that the PET tracer [18F]-T808 selectively targets neurofibrillary tangles (NFTs) of tau protein — a diagnostic biomarker for Alzheimer's disease.
"Efforts have been going on internally in my group for almost two years," Hartmuth Kolb, vice president of biomarker research at Siemens, told DOTmed News. "We have made around 800-900 compounds and two compounds, T807 and T808, have been the most promising."

Kolb led the research team, which designed, synthesized and tested these compounds in order to identify [18F]-PET tracers that possess strong binding affinity and selectivity toward these protein tangles.

Intercellular tangles of tau protein are one of two critical protein abnormalities associated with Alzheimer's disease, the other is amyloid plaque. Both pathologies are considered to be targets for therapeutic intervention, in addition to being biomarkers for diagnostic in vivo imaging agents, according to a statement from Siemens.

Kolb said NFTs could be an additional imaging biomarker for Alzheimer's because they can point to the degree of cognitive impairment and neuronal circuitry deterioration associated with Alzheimer's and dementia. Amyloid plaque build-up cannot provide these particulars.

"The expression of tau is more in synch with the actual symptoms of dementia," Kolb told DOTmed News. "Amyloid might be useful for early detection and tau might be useful for measuring the progression of the disease."

PETNET Solutions, a Siemens subsidiary, entered a deal last November with Eli Lilly & Company to manufacture and distribute Amyvid, an amyloid plaque PET imaging agentapproved by the FDA in April.

"The world has room for both and they both have different applications," said Kolb.

Siemens supported the tau protein research in its entirety and is leading the development of the [18F]-labeled compound as a potential PET imaging agent for commercialization. According to Kolb, clinical trials in human patients began a month ago at the University of California, Irvine.

"It looks like our hypothesis in ex vivo is also panning out in vivo, so it's promising."

Monday, September 3, 2012

Simple eyedrops can diagnose Alzheimer’s, prion diseases


Caregivers, and healthcare professionals, here is some great information

Here is a great dementia resource for caregivers and healthcare professinals,


Your residents will love the Amazon Kindle Fire


Here is information on being the best caregiver you can be


Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two


Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition

Smart Planet

Amyloids are these sticky plaques of protein that mark several different but related degenerative neural diseases, including Alzheimer’s, Parkinson’s, and prion diseases.

And because amyloids accumulate in the eye as well as the brain, diagnosing these diseases could one day be as simple as using eye drops and an eye exam.
To that end, researchers have devised several new fluorescent probes that change color depending on what type of amyloid they encounter, according to the University of California, San Diego news release.
“The key trick here is that the small differences in the proteins that make up different forms of amyloid interact differently with our fluorescent probes to result in measurably different colors of the emitted light,” says study researcher Jerry Yang of UCSD.
The colors vary depending on the physical properties of pockets in the different amyloid proteins:
Diagnostics that can distinguish between different, but closely related diseases – especially those where symptoms and pathological characteristics show many similarities – would be very important for deciding on effective treatment strategies for specific diseases.
By using an ointment or eye drops loaded with these fluorescent markers, doctors could light up amyloids in the eye in different colors. The technology has been licensed for commercial development of diagnostic tests for human neural disease.
The study is published in the Journal of the American Chemical Society 

Saturday, September 1, 2012

Dental health linked to dementia risk


Caregivers, and healthcare professionals, here is some great information

Here is a great dementia resource for caregivers and healthcare professinals,


Your residents will love the Amazon Kindle Fire


Here is information on being the best caregiver you can be


Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two


Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition

Reuters) - People who keep their teeth and gums healthy with regular brushing may have a lower risk of developing dementia later in life, according to a U.S. study.
Researchers at the University of California who followed nearly 5,500 elderly people over an 18-year-period found that those who reported brushing their teeth less than once a day were up to 65 percent more likely to develop dementia than those who brushed daily.
"Not only does the state of your mind predict what kind of oral health habits you practice, it may be that your oral health habits influence whether or not you get dementia," said Annlia Paganini-Hill, who led the study, published in the Journal of the American Geriatrics Society.
Inflammation stoked by gum disease-related bacteria is implicated in a host of conditions including heart disease, stroke and diabetes.
Some studies have also found that people with Alzheimer's disease, the most common form of dementia, have more gum disease-related bacteria in their brains than a person without Alzheimer's, Paganini-Hill said.
It's thought that gum disease bacteria might get into the brain, causing inflammation and brain damage, she said.
Paganini-Hill and her team followed 5,468 residents of a Californian retirement community from 1992 to 2010. Most people in the study were white, well-educated and relatively affluent. When the study began, participants ranged in age from 52 to 105, with an average age of 81.
All were free of dementia at the outset, when they answered questions about their dental health habits, the condition of their teeth and whether they wore dentures.
When the researchers followed up 18 years later, they used interviews, medical records and in some cases death certificates to determine that 1,145 of the original group had been diagnosed with dementia.
Of 78 women who said they brushed their teeth less than once a day in 1992, 21 had dementia by 2010, or about one case per 3.7 women.
n comparison, among those who brushed at least once a day, closer to one in every 4.5 women developed dementia which translates to a 65-percent greater chance of dementia among those who brushed less than daily.
Among the men, the effect was less pronounced with about one in six irregular brushers developing the disease, making them 22 percent more likely to have dementia than those who brushed daily. Statistically, however, the effect was so small it could have been due to chance, the researchers said.
Paganini-Hill could only speculate on the reasons for the different outcomes among men and women. Perhaps women wear their dentures more often than men and visit the dentist more frequently.
The study has limitation. Paganini-Hill and her team looked at behavior and tooth numbers as a kind of proxy for oral health and gum disease and didn't carry out any dental exams. While neglecting teeth might be a sign of early vulnerability to dementia, some other factor be having an impact too.
Head injury and malnutrition are also important causes of tooth loss in adults, and either of those might increase the dementia risk, said Amber Watts, who studies dementia at the University of Kansas and wasn't part of the study.
"I would be reluctant to draw the conclusion that brushing your teeth would definitely prevent you from getting Alzheimer's disease," she said. bit.ly/N5CCOu
(Reporting from New York by Natasja Sheriff at Reuters Health; editing by Elaine Lies and Bob Tourtellotte)

Blog Flux Directory
alzheimersideas - whereIstand.com

Fitness is important in dementia prevention. Click below for more info